27876534|t|Transcranial magnetic stimulation modifies astrocytosis, cell density and lipopolysaccharide levels in experimental autoimmune encephalomyelitis
27876534|a|Experimental autoimmune encephalomyelitis (EAE) is considered a valid experimental model for multiple sclerosis, a chronic neuroinflammatory condition of the central nervous system. Additionally, some evidence has shown that some microbial products such as the bacterial lipopolysaccharide could lead to the activation of reactive immune cells, triggering neuroinflammation. Several studies have found that transcranial magnetic stimulation (TMS) may exert a neuroprotective effect. Therefore, we aimed to assess the effect of TMS on the neuroinflammation occurring in EAE. A total of 44 male Dark Agouti rats were used. EAE induction was performed administering subcutaneously at the dorsal base of the tail a single dose of myelin oligodendrocyte glycoprotein. Clinical evaluation of motor symptoms was performed. Brain and spinal cord were collected and analyzed for nitric oxide, bacterial lipopolysaccharide and lipopolysaccharide-binding protein. We also carried out a histologic exam, which included an astrocyte immunostaining and Nissl staining for the assessment of brain cell density and pyknotic nuclei. TMS effectively ameliorated motor impairment secondary to EAE. This form of magnetic field was capable of decreasing the proliferation of astrocytes as a response to the autoimmune attack, reducing the content of nitric oxide, bacterial lipopolysaccharide and lipopolysaccharide-binding protein in central nervous system. Moreover, in treated animals, brain cell density was improved and the number of pyknotic nuclei was decreased. Transcranial magnetic stimulation modifies astrocytosis, cell density and lipopolysaccharide levels in EAE. These results suggest that TMS could be a promising treatment for neuroinflammatory conditions such as multiple sclerosis.
27876534	0	33	Transcranial magnetic stimulation	T061	C0436548
27876534	34	42	modifies	T169	C0392747
27876534	43	55	astrocytosis	T046	C3887640
27876534	57	69	cell density	T081	C0162339
27876534	74	92	lipopolysaccharide	T109	C0023810
27876534	93	99	levels	T080	C0441889
27876534	103	144	experimental autoimmune encephalomyelitis	T050	C0014072
27876534	145	186	Experimental autoimmune encephalomyelitis	T050	C0014072
27876534	188	191	EAE	T050	C0014072
27876534	209	233	valid experimental model	T170	C0086272
27876534	238	256	multiple sclerosis	T047	C0026769
27876534	260	295	chronic neuroinflammatory condition	T046	C0021368
27876534	303	325	central nervous system	T022	C3714787
27876534	346	354	evidence	T078	C3887511
27876534	375	384	microbial	T001	C0599840
27876534	385	393	products	T071	C1514468
27876534	406	434	bacterial lipopolysaccharide	T109	C0023810
27876534	453	488	activation of reactive immune cells	T043	C1155000
27876534	490	500	triggering	T201	C0032930
27876534	501	518	neuroinflammation	T046	C0021368
27876534	528	535	studies	T062	C2603343
27876534	552	585	transcranial magnetic stimulation	T061	C0436548
27876534	587	590	TMS	T061	C0436548
27876534	596	601	exert	T040	C0015264
27876534	604	626	neuroprotective effect	T169	C0815279
27876534	651	657	assess	T058	C0184514
27876534	662	668	effect	T080	C1280500
27876534	672	675	TMS	T061	C0436548
27876534	683	700	neuroinflammation	T046	C0021368
27876534	714	717	EAE	T050	C0014072
27876534	733	737	male	T032	C0086582
27876534	738	754	Dark Agouti rats	T015	C0086893
27876534	766	769	EAE	T050	C0014072
27876534	770	779	induction	T169	C0205263
27876534	794	822	administering subcutaneously	T058	C4032485
27876534	830	853	dorsal base of the tail	T023	C3686729
27876534	856	867	single dose	T081	C0178602
27876534	871	906	myelin oligodendrocyte glycoprotein	T116,T123	C0069428
27876534	908	927	Clinical evaluation	T058	C4084924
27876534	931	945	motor symptoms	T184	C0426980
27876534	961	982	Brain and spinal cord	T023	C0545988
27876534	988	997	collected	T169	C1516698
27876534	1002	1010	analyzed	T062	C0936012
27876534	1015	1027	nitric oxide	T121,T123,T197	C0028128
27876534	1029	1038	bacterial	T080	C0521009
27876534	1039	1057	lipopolysaccharide	T109	C0023810
27876534	1062	1096	lipopolysaccharide-binding protein	T116,T123	C0065054
27876534	1120	1135	histologic exam	T059	C0019637
27876534	1155	1164	astrocyte	T025	C0004112
27876534	1165	1179	immunostaining	T059	C0487602
27876534	1184	1198	Nissl staining	T059	C0487602
27876534	1207	1217	assessment	T058	C0184514
27876534	1221	1226	brain	T023	C0006104
27876534	1227	1239	cell density	T081	C0162339
27876534	1244	1259	pyknotic nuclei	T026	C0007610
27876534	1261	1264	TMS	T061	C0436548
27876534	1265	1276	effectively	T080	C1704419
27876534	1289	1294	motor	T038	C0234130
27876534	1295	1305	impairment	T169	C0221099
27876534	1306	1318	secondary to	T080	C0175668
27876534	1319	1322	EAE	T050	C0014072
27876534	1337	1351	magnetic field	T070	C0563533
27876534	1367	1377	decreasing	T033	C0442797
27876534	1382	1395	proliferation	T169	C1514485
27876534	1399	1409	astrocytes	T025	C0004112
27876534	1431	1448	autoimmune attack	T046	C0443146
27876534	1450	1458	reducing	T080	C0392756
27876534	1474	1486	nitric oxide	T121,T123,T197	C0028128
27876534	1488	1497	bacterial	T080	C0521009
27876534	1498	1516	lipopolysaccharide	T109	C0023810
27876534	1521	1555	lipopolysaccharide-binding protein	T116,T123	C0065054
27876534	1559	1581	central nervous system	T022	C3714787
27876534	1596	1603	treated	T169	C1522326
27876534	1604	1611	animals	T008	C0003062
27876534	1613	1618	brain	T023	C0006104
27876534	1619	1631	cell density	T081	C0162339
27876534	1636	1644	improved	T033	C0184511
27876534	1663	1678	pyknotic nuclei	T026	C0007610
27876534	1683	1692	decreased	T081	C0205216
27876534	1694	1727	Transcranial magnetic stimulation	T061	C0436548
27876534	1728	1736	modifies	T169	C0392747
27876534	1737	1749	astrocytosis	T046	C3887640
27876534	1751	1763	cell density	T081	C0162339
27876534	1768	1786	lipopolysaccharide	T109	C0023810
27876534	1787	1793	levels	T080	C0441889
27876534	1797	1800	EAE	T050	C0014072
27876534	1829	1832	TMS	T061	C0436548
27876534	1844	1863	promising treatment	T061	C0087111
27876534	1868	1896	neuroinflammatory conditions	T046	C0021368
27876534	1905	1923	multiple sclerosis	T047	C0026769